Filtered By:
Drug: Beta-Blockers

This page shows you your search results in order of date.

Order by Relevance | Date

Total 494 results found since Jan 2013.

How To Avoid China ’ s Medicine Monopoly
I want to share a shocking statistic with you… Around 80% of all the pharmaceuticals sold in America — both prescription and over-the-counter — are manufactured in China. I’m talking about drugs for Parkinson’s and Alzheimer’s, blood pressure and blood thinners, diuretics, aspirin, antibiotics, and a big chunk of the world’s insulin and diabetes drugs — just to name a few.1 We don’t even make penicillin anymore. The last penicillin plant in the U.S. closed its doors in 2004. Americans who rely on medicine are now almost entirely at the mercy of a country whose relations with the U.S. have become more ...
Source: Al Sears, MD Natural Remedies - September 19, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Source Type: news

Differential Cardiovascular Outcomes of Each Antihypertensive Drug Class in Patients With Hypertension and Breast Cancer Undergoing Doxorubicin-Containing Chemotherapy
CONCLUSION: RAS inhibitors are preferred for the treating hypertension and improving CV outcomes in patients with hypertension and breast cancer undergoing DOX-containing chemotherapy, particularly in patients with comorbid diabetes. However, CCBs are equivalent to RAS inhibitors and are more favorable than BBs and TDs in terms of improving CV outcomes.PMID:37704380 | DOI:10.4048/jbc.2023.26.e34
Source: Journal of Breast Cancer - September 13, 2023 Category: Cancer & Oncology Authors: Hui-Jeong Hwang Sang-Ah Han Source Type: research

Blocking interleukin-6 Trans-Signaling in AF: Promises and Challenges
Atrial fibrillation (AF) stands as the most prevalent cardiovascular disease, posing significant risks of stroke, heart failure, and other complications that contribute to morbidity and mortality. While traditionally research on AF has primarily focused on electrophysiological components like ionic currents and the Ca2+ handling system, treatment strategies have mainly revolved around the rate-limiting beta-blockers and Ca2+ channel blockers, or rhythm-control methods such as cardioversion, antiarrhythmics, and catheter ablation.
Source: Heart Rhythm - September 9, 2023 Category: Cardiology Authors: Enrique Martinez, Na Li Source Type: research

Effect of Beta-Blocker on Long-Term Major Cardiovascular Events in High Atherosclerotic Risk Population
CONCLUSION: In patients with high atherosclerotic cardiovascular risk, taking beta-blockers had a higher risk of 3P-MACEs. Care should be taken when prescribing beta-blockers to patients without a clear indication.TRIAL REGISTRATION: TCTR20130520001 registered in Thai Clinical Trials Registry (TCTR) https://www.thaiclinicaltrials.org/ , date of registration 20 May 2013.PMID:37594650 | DOI:10.1007/s10557-023-07502-8
Source: Atherosclerosis - August 18, 2023 Category: Cardiology Authors: Nichanan Osataphan Kamol Udol Khanchai Siriwattana Bancha Sukanandachai Siriluck Gunaparn Wachiranun Sirikul Arintaya Phrommintikul Wanwarang Wongcharoen Source Type: research

Impact of age on characteristics, performance measures and outcomes of inpatients for heart failure in Beijing, China
ConclusionsHF patients aged ≥75 years had distinct clinical profiles, received worse in-hospital therapies and experienced higher in-hospital and 1 year mortality.
Source: ESC Heart Failure - August 2, 2023 Category: Cardiology Authors: Cong Yuan, Liu He, Xin Du, Chao Jiang, Shi ‐Jun Xia, Xin Zhao, Song‐Nan Li, Cai‐Hua Sang, De‐Yong Long, Jian‐Zeng Dong, Chang‐Sheng Ma Tags: Original Article Source Type: research

Tizanidine induced hypotension: report of a case and review of literature
CONCLUSION: This patient highlights the need for close monitoring of patients receiving tizanidine co-medication with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. These drugs have a synergistic effect on reducing the renin-angiotensin-aldosterone system, thereby hypotension and bradycardia.PMID:37489780 | DOI:10.2174/1574886318666230725113855
Source: Current Drug Safety - July 25, 2023 Category: Drugs & Pharmacology Authors: Roopali Mahajan Jayantee Kalita Source Type: research